The Medical Services sector is undergoing a rapid transformation driven by advances in digital health, wider adoption of value-based care and a stronger focus on patient-centric and precision medicine solutions. Demand for remote treatment continues to accelerate growth in telemedicine and AI-powered analytics, with providers using these tools to improve diagnostics, streamline operations and deliver more personalized, preventive care. According to a Precedence Research report, the global healthcare analyti ...

Core Viewpoint - Lytus Technologies Holdings PTV. Ltd. plans to implement a reverse stock split at a ratio of 1-for-2,500 to increase the market price of its common shares and meet NYSE American listing requirements [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect on September 26, 2025, and trading will commence on a split-adjusted basis under the existing symbol "LYTHF" [2]. - No fractional shares will be issued; any resulting fractional shares will be rounded up to the next whole number [4]. Group 2: Company Background - Lytus Technologies is a platform services company primarily operating in India, focusing on linear content streaming, telemedicine, and fintech [5]. - The company aims to consolidate its subscriber base for future technology services while enhancing its technology platform for improved service delivery [5].

Core Viewpoint - Lytus Technologies Holdings PTV. Ltd. plans to implement a reverse stock split at a ratio of 1-for-2,500 to increase the market price of its common shares and meet NYSE American listing requirements [1][3]. Company Announcement - The reverse stock split will take effect on September 26, 2025, and trading will commence on a split-adjusted basis under the existing symbol "LYTHF" [2]. - The new CUSIP number for the common shares post-split will be G5851A141 [2]. Purpose of the Reverse Stock Split - The primary goal of the reverse stock split is to enhance the market price of the shares, which is essential for the company to pursue uplisting to a national securities exchange [3]. Shareholder Information - VStock Transfer LLC will act as the transfer agent and will provide instructions to shareholders regarding the exchange of shares [3]. - Shareholders holding shares in book-entry form or brokerage accounts will not need to take any action for the exchange [3]. Fractional Shares - No fractional common shares will be issued; any resulting fractional shares will be rounded up to the next whole number [4]. Company Overview - Lytus Technologies Holdings PTV. Ltd. operates primarily in India, focusing on platform services, including linear content streaming and technology product development in telemedicine and fintech [5]. - The company aims to consolidate its subscriber base for future technology services while enhancing its technology platform for improved service delivery [5]. - Lytus is involved in various sectors, including digital streaming, HealthTech, fintech, AI, and cybersecurity, and operates in both domestic and international markets [5].

Company Overview - Mobile-health Network Solutions (MNDR) is a leading AI-powered digital healthcare platform provider headquartered in Singapore, with operations across Southeast Asia and plans to expand into the US [5] - The company offers telemedicine, AI-driven health tools, and virtual clinic infrastructure aimed at making healthcare accessible and intelligent through technology [5] Reverse Stock Split Announcement - MNDR announced a one-for-five reverse stock split effective at 12:01 a.m. Eastern Time on September 25, 2025, reducing the number of outstanding shares from approximately 4,684,779 to about 936,956 [1][2] - The number of authorized shares will decrease from 781,250,000 to 156,250,000, and the par value per share will change from $0.000032 to $0.00016 [2] Shareholder Communication and Process - VStock Transfer, LLC will act as the transfer agent, notifying stockholders of record and issuing post-split shares in paperless "book-entry" form [3] - Shareholders with certificated shares will receive instructions on how to surrender their certificates, while those holding shares in "street name" will have their positions automatically adjusted [3] Strategic Implications - The completion of the reverse stock split is seen as a significant advantage for MNDR in retaining its Nasdaq listing, which aligns with the company's strategic objectives [5]

Core Insights - Mobile-health Network Solutions (MNDR) has secured a strategic investment of US$900,000 from Indopacific Health Investment Corporation to enhance its growth strategy and market entry in Indonesia [1][3] - The investment follows an earlier subscription of US$150,000 in May 2025, bringing Indopacific's total investment in MNDR to US$1.05 million [3] - The funds will primarily be allocated for the acquisition of Lifepack, a digital pharmacy platform in Indonesia, and to support broader market initiatives across Southeast Asia [3][4] Investment Details - The share purchase was executed under a Securities Purchase Agreement dated September 10, 2025, with shares priced at US$1.80 each [2] - The transaction includes customary closing conditions and lock-up provisions in accordance with Nasdaq requirements [2] Company Overview - Mobile-health Network Solutions is an AI-powered digital health platform based in Singapore, with operations across Southeast Asia and plans to expand into the US [5] - The company focuses on providing telemedicine, AI-driven health tools, and virtual clinic infrastructure to enhance healthcare accessibility [5]

Core Insights - LifeMD, Inc. reported strong financial results for Q1 2025, achieving its first-ever quarter of GAAP profitability ahead of expectations [3][5] - The company experienced significant growth in telehealth services, with a 70% year-over-year increase in telehealth revenue [5][8] - LifeMD raised its full-year 2025 guidance for total revenues and adjusted EBITDA, reflecting robust performance in the telehealth segment [5][14] Financial Performance - Total revenues increased by 49% year-over-year to $65.7 million, with telehealth revenue contributing $52.5 million [8][9] - Adjusted EBITDA rose to $8.7 million from $0.1 million in the same period last year [9][30] - GAAP net income was reported at $0.6 million, or $0.01 per diluted share, compared to a net loss of $7.5 million, or ($0.19) per share, in Q1 2024 [9][21] Subscriber Growth - Telehealth active subscribers increased by 22% to approximately 290,000 [9][10] - Total active subscribers across all services reached 448,925, marking an 11% increase year-over-year [10] Strategic Initiatives - LifeMD expanded its service offerings, including the launch of men's hormone therapy and acceptance of Medicare, which are expected to enhance its telehealth platform [3][4] - The company formed strategic collaborations with LillyDirect and NovoCare to provide access to branded GLP-1 medications, positioning itself as a unique telehealth provider in the U.S. [4] Financial Guidance - For the full year 2025, LifeMD expects total revenues in the range of $268 million to $275 million, up from previous guidance of $265 million to $275 million [5][14] - Adjusted EBITDA guidance was raised to a range of $31 million to $33 million, reflecting strong year-to-date performance [5][14]